Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,373.98 -43.70 -0.30%
TOPIX 1,164.81 -1.74 -0.15%
HANG SENG 22,749.87 53.86 0.24%

Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury



Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the
Treatment of Muscle Injury

First Time Surgically Induced Muscle Injury Treated With PLX Cells

HAIFA, Israel, March 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, today reported on the progress of its ongoing double blind Phase
I/II clinical trial to test the safety and efficacy of its PLacental Expanded
(PLX) cells in the treatment of muscle injury. This is the first time PLX
cells have been used in patients following surgically induced muscle trauma.

The study is being conducted at the Orthopedic Clinic on the campus of the
Charité University Medical School in Berlin, Germany. The muscle injury being
studied is the gluteal buttock muscle that has been surgically traumatized
during hip replacement surgery. The primary endpoint of the study is safety
with a secondary endpoint of gluteal muscle function at 6 months with the
ability to perform biopsies of the involved muscle. PLX cells will be injected
directly into the surgical incision after it has been sutured. Three groups of
six patients will be enrolled in the study. From each group of six patients,
two patients will receive a high dose of PLX cells, two patients will receive
a low dose of PLX cells and two patients will receive placebo. The first group
of six patients has been dosed without a significant adverse event related to
either the placebo or the PLX cell product candidate.

"We are very pleased with the progress of enrollment in this trial to date,"
stated Zami Aberman, Chairman and CEO of Pluristem. "This is the first time
PLX cells have been used in addressing surgically induced muscle injury and a
positive response will give us an indication of the potential of PLX cells for
this indication as well as non-surgical injuries such as sports injuries."

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, we are using forward-looking
statements when we discuss the progress made in our Phase I/II clinical trial
of PLX cells for the treatment of muscle injury, or when we discuss how a
positive response in this clinical trial will give us an indication of the
potential of PLX cells for this indication as well as non-surgical injuries.
These forward-looking statements and their implications are based on the
current expectations of the management of Pluristem only, and are subject to a
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement